Oncology Corporate Profile
Novartis offers a wide range of healthcare products through its Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions. Its Pharmaceuticals division researches, develops, manufactures, distributes, and sells pharmaceuticals in therapeutic areas including oncology, hematology and many other areas.
|Afinitor®||everolimus||Afinitor® is a kinase inhibitor indicated for the treatment of:|
• postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
• adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. The safety and effectiveness of AFINITOR in the treatment of patients with carcinoid tumors have not been established.
• adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
• adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes.
Afinitor® and Afinitor® Disperz are kinase inhibitors indicated for the treatment of:
• pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated.
|Exjade®||deferasirox||Exjade® (deferasirox) is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.|
|Farydak®||panobinostat||Farydak®, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD|
|Femara®||letrozole||Femara® is an aromatase inhibitor indicated for:|
-Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
-Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
-First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
|Gleevec®||imatinib mesylate||Gleevec® is a kinase inhibitor indicated for the treatment of:|
• Newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Follow-up is limited to 5 years
• Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy
• Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. There are no controlled trials in pediatric patients demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival
• Adult patients with relapsed or refractory Philadelphia chromosome
positive acute lymphoblastic leukemia (Ph+ ALL)
• Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
• Adult patients with aggressive systemic mastocytosis (ASM) without the
D816V c-Kit mutation or with c-Kit mutational status unknown
• Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1- PDGFR fusion kinase negative or unknown
• Adult patients with unresectable, recurrent and/or metastatic
dermatofibrosarcoma protuberans (DFSP)
Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
|Kisqali®||ribociclib||Kisqali® is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.|
|Kisqali® Femara® Co-Pack||ribociclib tablets; letrozole tablets||Kisqali® is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Femara® is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy; first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.|
|Odomzo®||sonidegib||Odomzo® (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy|
|Rydapt®||midostaurin||Rydapt® is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Rydapt® is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).|
|Sandostatin®||octreotide acetate||Long-term maintenance therapy for acromegaly and the treatment of symptoms related to carcinoid syndrome and VIPomas.|
|Tafinlar® + Mekinist®||dabrafenib + trametinib||Tafinlar® in combination wit Mekinist® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.|
|Tasigna®||nilotinib||Tasigna® is a kinase inhibitor indicated for:|
-The treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
-The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
|Zometa®||zoledronic acid||Zometa® is a bisphosphonate indicated for the treatment of:|
• Hypercalcemia of malignancy
• Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy
Important limitation of use: The safety and efficacy of Zometa® has not been established for use in hyperparathyroidism or non tumor-related hypercalcemia.
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|dovitinib / TKI258||multiple tyrosine kinase inhibitor||1st line metastatic Renal cell carcinoma (RCC)||III|
|midostaurine / PKC412||multikinase inhibitor||Acute Myelogenous Leukemia (AML)||III|
|LDE225||smoothened antagonist||Basal Cell Carcinoma (BCC)||III|
|LEE011||CDK4/6 inhibitor||Breast cancer||III|
|BKM120||PI3K inhibitor||Breast cancer||III|
|alpelisib / BYL719||PI3K® inhibitor||HR+/HER2- advanced Breast cancer||III|
|SOM230||somatostatin analog||Neuroendocrine tumor||III|
|patupilone / EPO906||epothilone||Ovarian cancer||III|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||1st line metastatic Breast cancer||III||Antisoma|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||III||Antisoma|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||Neuroendocrine tumor||III||Antisoma|
|Arzerra® / ofatumumab||Anti-CD20 monoclonal antibody||Refractory Non-Hodgkin's Lymphoma (NHL)||III|
|Gleevec® / imatinib mesylate||multiple tyrosine kinase inhibitor||Adjuvant Gastrointestinal Stromal Tumor (GIST)||III|
|Tasigna® / nilotinib||multiple tyrosine kinase inhibitor||1st line metastatic Chronic Myelogenous Leukemia (CML)||III|
|Tasigna® / nilotinib||multiple tyrosine kinase inhibitor||Gastrointestinal Stromal Tumors (GIST)||III|
|Zometa® / zoledronic acid||bisphosphonate||Breast cancer||III|
|Zometa® / zoledronic acid||bisphosphonate||Multiple Myeloma||III|
|patupilone / EPO906||epothilone||1st line metastatic Hepatocellular carcinoma (HCC)||II|
|LDK378||ALK inhibitor||2nd line ALK+ metastatic Non Small Cell Lung Cancer (NSCLC)||II|
|panobinostat / LBH589||pan-DAC inhibitor||2nd line metastatic Hodgkin's Lymphoma||II|
|tisagenlecleucel-T / CTL019||CD19-targeted chimeric antigen receptor T-cell immunotherapy||Acute Lymphocytic Leukemia (ALL)||II|
|patupilone / EPO906||epothilone||Brain Metastases||II|
|LCL161||IAP inhibitor||Breast cancer||II|
|panobinostat / LBH589||pan-DAC inhibitor||Cutaneous T-cell Lymphoma (CTCL)||II|
|BGJ398||pim-1 inhibitor||Glioblastoma Multiforme (GBM)||II|
|SOM230||somatostatin analog||Neuroendocrine tumor||II|
|AUY922||Hsp90 inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|capmatinib / INC280||c-Met kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|patupilone / EPO906||epothilone||Various cancer types||II|
|BGJ398||FGF-R kinase inhibitor||Various cancer types||II|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||Brain cancer||II||Antisoma|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||Mantle Cell Lymphoma (MCL)||II||Antisoma|
|Afinitor® / everolimus / RAD001||mTOR inhibitor||Various cancer types||II||Antisoma|
|Gleevec® / imatinib mesylate||multiple tyrosine kinase inhibitor||1st line metastatic Melanoma||II|
|Odomzo® / sonidegib||hedgehog pathway inhibitor||Leukemia||II|
|Odomzo® / sonidegib||hedgehog pathway inhibitor||medulloblastoma||II|
|Promacta® / eltrombopag||thrombopoietin receptor agonist||Acute Myelogenous Leukemia (AML)||II|
|Promacta® / eltrombopag||thrombopoietin agonist||Chemotherapy-induced thrombocytopenia||II|
|asciminib / ABL001||BCR-ABL inhibitor||3rd line chronic myelogenous Leukemia (CML)||I|
|LFA102||anti-prolactin receptor mAb||Breast cancer||I|
|AUY922||Hsp90 inhibitor||Breast cancer||I|
|ABL 001||Bcr-abl tyrosine kinase inhibitor||Chronic Myelogenous Leukemia (CML)||I|
|BKM120||PI3K inhibitor||Glioblastoma Multiforme (GBM)||I|
|AEE788||ErbB/VEGF inhibitor||Glioblastoma Multiforme (GBM)||I|
|ABL 001||Bcr-abl tyrosine kinase inhibitor||Leukemia||I|
|RAF265||Raf and VEGFR kinase inhibitor||Melanoma||I|
|LGH447||proto oncogene protein c||Myelodysplastic Syndrome (MDS)||I|
|EGF816||EGFR TK inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|BEZ235||PI3K inhibitor (oral)||Various cancer types||I|
|LDE225||smoothened antagonist||Various cancer types||I|
|BGT226||PI3K inhibitor||Various cancer types||I|
|panobinostat / LBH589||pan-DAC inhibitor||Various cancer types||I|
|dovitinib / TKI258||multiple tyrosine kinase inhibitor||Various cancer types||I|
|AUY922||Hsp90 inhibitor||Various cancer types||I|
|LBY135||anti-DR5 monoclonal antibody||Various cancer types||I|
|BHQ880||anti-DKK1 monoclonal antibody||Various cancer types||I|
|lucatumumab / HCD122||anti-CD40 monoclonal antibody (humanized)||Various cancer types||I||Xoma|
|HDM201||tumor suppressor protein p53 modulator||Various cancer types||I|
|HSC835||stem cell therapy||Various cancer types||I|
|ASB183||mTOR inhibitor||Various cancer types||I|
|PIM447||Pan-PIM inhibitor||Various cancer types||I|
|Tasigna® / nilotinib||multiple tyrosine kinase inhibitor||Acute Lymphocytic Leukemia (ALL)||I|
|Zykadia / certinib||ALK inhibitor||2nd line ALK+ metastatic Non Small Cell Lung Cancer (NSCLC)||Approved|
View additional information on product candidates here »
11/2/2016 11:33 am
(STAT/Pharmalot) Nov 1, 2016 - For the past four years, Novartis has refuted charges of unfairly pricing a key cancer treatment in Colombia. Internal company data show, though, that the drug maker had also charged much more in the Latin American nation for three other widely used medicines than in dozens of other countries.
11/1/2016 11:08 am
(FoxNews.com/Reuters) Nov 1, 2016 - The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug.
11/1/2016 06:59 am
(Novartis) Nov 1, 2016 - Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to letrozole alone; underscores potential of LEE011 plus letrozole as a new treatment option for advanced breast cancer; may lead to faster access for US patients.
10/31/2016 10:39 am
(Novartis) Oct 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.
10/26/2016 11:46 am
(Bloomberg/Markets blog) Oct 25, 2016 - Novartis AG, Europe’s second-biggest drugmaker by sales, said it’s looking for acquisitions that cost between $2 billion and $5 billion to bolster its position in areas including cancer and the development of copycat medicines.
10/25/2016 12:36 pm
(Reuters) Oct 25, 2016 - Novartis expects a more difficult pricing environment for drugs in the United States in the years ahead, its chief executive told a results conference call on Tuesday.
10/10/2016 10:11 am
(StreetInsider) Oct 9, 2016 - Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients taking Zykadia® (ceritinib) as their first ALK inhibitor (post-chemotherapy) had a median progression-free survival (PFS) of 18.4 months [95% CI: 10.9-26.3; median follow-up time of 25.9 months, as measured by blinded independent review committee (BIRC)].
10/10/2016 10:11 am
(MarketWatch) Oct 8, 2016 – Novartis today announced data from the Phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) compared to vemurafenib mono therapy.
10/10/2016 10:10 am
(Yahoo! Finance) Oct 8, 2016 - Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months - not reached) vs. 14.7 months (13.0 - 16.5 months); HR=0.556; p=0.00000329).
10/10/2016 09:45 am
(Bloomberg) Oct 8, 2016 - An experimental Novartis AG treatment for a form of advanced breast cancer slashed the risks of death and the disease progressing in a study, paving the way for the Swiss drugmaker to seek regulatory approval in the U.S. and Europe by the end of the year.
9/23/2016 10:52 am
(Reuters) Sept 23, 2016 - Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug.
9/23/2016 07:20 am
(Novartis) Sept 23, 2016 - Novartis today announced top-line results from its Phase III ASCEND-4 clinical study for Zykadia® (ceritinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.
9/19/2016 11:52 am
(Reuters) Sept 17, 2016 - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial.
9/14/2016 11:56 am
(Novartis Oncology) Sept 14, 2016 - 89% of metastatic breast cancer patients surveyed feel it’s important to discuss a long-term treatment “roadmap” with their doctor at initial diagnosis, yet 43% report not having that conversation; patients seek comprehensive dialogue with oncologists to understand treatment options and quality of life issues throughout the course of their disease; results led to a community-endorsed personalized discussion guide to help improve communications between patients and oncologists.
9/1/2016 11:10 am
(Forbes) Aug 31, 2016 - Novartis is shutting down the business unit it created to develop white blood cells that can attack certain types of cancer, but continuing to develop such projects known as chimeric antigen receptor T-cells, or CAR-Ts.
9/1/2016 07:07 am
(Bloomberg) Aug 31, 2016 - Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment.
8/31/2016 11:16 am
(Boston Globe/Associated Press) Aug 31, 2016 - US regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
8/25/2016 11:46 am
(Reuters) Aug 25, 2016 - Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
8/25/2016 11:19 am
(Penn Medicine) Aug 25, 2016 - Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of Translational Research in Penn’s Abramson Cancer Center, has been awarded a 2016 Novartis Prize for Clinical Immunotherapy.
8/18/2016 07:17 am
(European Pharmaceutical Review) Aug 18, 2016 - In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective.
8/11/2016 11:40 am
(Forbes) Aug 11, 2016 - A few years ago, researchers at Novartis saw a disconnect between its robust cancer drug development pipeline, and the speed and efficacy by which it tested small molecules on real tumors. So it innovated the way it conducts early-stage research.
8/10/2016 11:19 am
(STAT) Aug 9, 2016 - Six former and current Novartis executives at its Korean unit were indicted Monday on charges of paying more than $2 million to doctors in return for prescribing its medicines, a company spokesman confirmed. Among those indicted was the former chief executive in the country.
8/8/2016 11:28 am
(Reuters) Aug 6, 2016 - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.
8/3/2016 10:36 am
(PharmaTimes [UK]) Aug 3, 2016 - Novartis' experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) has picked up a Breakthrough Therapy designation in the US for the treatment of certain forms of breast cancer.
8/3/2016 06:48 am
(Novartis) Aug 3, 2016 - Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective cyclin dependent kinase (CDK4/6) inhibitor.
6/23/2016 10:05 am
(UPMC) June 23, 2016 - Potent doses of broccoli sprout extract activate a “detoxification” gene and may help prevent cancer recurrence in survivors of head and neck cancer, according to a trial by the University of Pittsburgh Cancer Institute, partner with UPMC Cancer Center, confirming preliminary results presented last year at the American Association for Cancer Research Annual Meeting.
6/21/2016 12:01 pm
(Dana-Farber) June 20, 2016 - Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
6/21/2016 12:01 pm
(Mass General) June 20, 2016 - A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators – individuals who assist patients in receiving health care services – may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.
6/20/2016 12:02 pm
(Reuters) June 20, 2016 - Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.
6/15/2016 12:00 pm
(ACCCBuzz) June 15, 2016 - ACCC recently held its first Financial Advocacy Network (FAN) Case-Based Workshop of 2016.
6/15/2016 11:05 am
(AACR) June 15, 2016 - Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy may help in preventing the cancer from coming back, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
6/9/2016 11:02 am
(MedCity News) June 8, 2016 - So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
6/5/2016 05:05 pm
(Reuters) June 5, 2016 - Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.
6/5/2016 05:05 pm
(NBC News) June 5, 2016 - A newly approved drug that gives the immune system a boost helped stall the spread of tumors in patients with advanced bladder cancer, researchers reported Sunday.
6/4/2016 06:00 pm
(Reuters) June 3, 2016 - U.S. Food and Drug Administration staff released voting questions on Teva Pharmaceutical Industries Ltd's long-acting opioid painkiller for a panel of independent experts who will recommend to the agency whether to approve the drug.
6/4/2016 05:03 pm
(Benzinga) June 4, 2016 - Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program.
6/4/2016 05:01 pm
(The Business Journals) June 4, 2016 - Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potentially substantial therapeutic benefit of genomic profiling in serious, life-threatening cancers.
5/23/2016 12:01 pm
(STAT/Pharmalot) May 19, 2016 - In less than a month, Vermont could become the first state in the country to require drug makers to justify price hikes on their medicines, a move that may prompt others to take similar action but also spark a battle with the pharmaceutical industry.
5/19/2016 12:03 pm
(bizjournals.com) May 19, 2016 - Study to evaluate MM-151 in combination with ONIVYDE plus fluorouracil and leucovorin.
5/19/2016 12:02 pm
(Pfizer) May 18, 2016 - 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer; two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma; data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers; JAVELIN clinical program rapidly accelerating.
5/18/2016 12:04 pm
(ABC News/Associated Press) May 18, 2016 - Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.
5/17/2016 12:00 pm
(Medscape Medical News) May 16, 2016 - A new bill introduced in the Senate is designed to increase access to experimental drugs for dying patients and circumvent the FDA.
5/5/2016 11:04 am
(Yahoo! Finance) May 4, 2016 - RedHill Biopharma Ltd. today announced that the U.S. National Cancer Institute (“NCI”) has awarded the Medical University of South Carolina (“MUSC”) a $1.8 million grant to support a broad range of studies on the feasibility of targeting sphingolipid metabolism for the treatment of a variety of solid tumor cancers.
5/5/2016 11:01 am
(Morningstar) May 4, 2016 - SELLAS Life Sciences Group today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) were presented at the plenary session of the iMig 2016 Conference, being held May 1-4, 2016, in Birmingham, UK.
5/2/2016 11:01 am
(Institute of Cancer Research [UK]) May 1, 2016 - Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.
5/2/2016 11:01 am
(University of Birmingham [UK]) Apr 28, 2016 - Research into bladder tumour surgery has found that using narrow band imaging can significantly reduce the risk of disease recurrence.
4/26/2016 12:00 pm
(FDA.gov) Apr 25, 2016 - On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
4/25/2016 11:04 am
(ACCC) Apr 21, 2016 - The Centers for Medicare & Medicaid Services (CMS) announced that the deadline for submission of a Next Generation ACO Model Letter of Intent (LOI) has been extended to May 20, 2016.
4/20/2016 12:01 pm
(Astex) Apr 19, 2016 - Astex Pharmaceuticals, Inc. announced today that it has entered into a clinical collaboration with Genentech to evaluate the potential for combining Astex’s next generation hypomethylating agent, guadecitabine (SGI-110), with Genentech’s investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML).
4/20/2016 11:05 am
(Yahoo! Finance) Apr 19, 2016 - OncoSec Medical Incorporated today presented long-term, follow-up data of patients who were treated with its investigational therapy ImmunoPulse™ IL-12 and later went on to receive an anti-PD-1/PD-L1 therapy.